Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harmony Biosciences HoldingsHRMY 96 Equity-to-Asset is 0.73 as of Jun. 2026, which is 22% above its 10-year median of 0.60. GuruFocus rates HRMY with a GF Score™ of 96/100 and a GF Value™ of $47.14 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Harmony Biosciences Holdings ranks better than 56.29% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Harmony Biosciences Holdings Equity-to-Asset Related Terms
Harmony Biosciences Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HRMY vs OCUL, MLYS, BHVN: Equity-to-Asset Comparison
For the Biotechnology subindustry, Harmony Biosciences Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Harmony Biosciences Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings (HRMY) has a Equity-to-Asset of 0.73 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Harmony Biosciences Holdings and its competitors. This is 22% above median its historical median of 0.60. According to the industry distribution chart, Harmony Biosciences Holdings ranks #618 out of 1414 companies in the Biotechnology industry, placing it in the top 43.7%.
Is Harmony Biosciences Holdings' Equity-to-Asset too high?
Harmony Biosciences Holdings' current Equity-to-Asset of 0.73 is 22% above median its 10-year median of 0.60. The Biotechnology industry median Equity-to-Asset is 0.68. Harmony Biosciences Holdings' value of 0.73 is 7.4% above this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #618 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Harmony Biosciences Holdings has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Equity-to-Asset compare to OCUL and MLYS?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #618 out of 1414 companies for Equity-to-Asset. This puts Harmony Biosciences Holdings in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Harmony Biosciences Holdings' value of 0.73 is 7.4% above this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 0.68, Harmony Biosciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current Equity-to-Asset of 0.73 is 7.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Harmony Biosciences Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current Equity-to-Asset is 0.73, which is 22% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $47.14, compared to a current price of $41.62 — trading 11.7% below its estimated fair value. The current Equity-to-Asset is 0.73, which is 22% above median its 10-year median of 0.60 and 7.4% above the Biotechnology industry median of 0.68. Harmony Biosciences Holdings' overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Equity-to-Asset is 0.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $41.62 is trading 11.7% below its estimated GF Value™ of $47.14.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
Equity-to-Asset: 0.73 (22% above median its 10-year median of 0.60)
GF Value™: $47.14 vs. price of $41.62 (11.7% below fair value)
Industry Position: 7.4% above the Biotechnology median (#618 of 1414)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
96GF Score
Get the complete analysis for HRMY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
